Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2022 June Science Adolscent and young adult leukaemia survivors face higher mortality than general population Read more
2022 June Pharma News FDA approves the frontline use of ivosidenib in AML patients with IDH1 mutation Read more
2022 June Clinical trials Chemoradiation limits but does not eliminate excess long-term morbidity in cHL patients Read more
2022 June Clinical trials Gilteritinib maintenance improves overall survival in relapsed /refractory FLT3+ AML Read more
Top
